Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function - 06/06/19
Doi : 10.1016/j.jaci.2019.02.015
Clare Hardman, PhD a, Wentao Chen, MSc b, Jian Luo, MD b, Paul Batty, MSc b, Yi-Ling Chen, DPhil a, Janina Nahler, BSc a, Yanqiu Wu, MM b, Ian D. Pavord, F Med Sci b, Veit J. Erpenbeck, MD c, David A. Sandham, PhD d, ∗, Luzheng Xue, PhD b, ∗, Graham Ogg, BMBCh DPhil a, ∗ 
a MRC Human Immunology Unit and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
b Respiratory Medicine Unit and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
c Novartis Pharma AG, Basel, Switzerland
d Novartis Institutes for Biomedical Research, Cambridge, Mass
| Supported by a research grant to G.O. and L.X. from Novartis administered through the University of Oxford. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute of Health Research (NIHR), or the Department of Health. |
|
| Disclosure of potential conflict of interest: I. D. Pavord has received speaker's honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, and GlaxoSmithKline and payments for organizing educational events from AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron, and Teva; has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Merck, Circassia, Chiesi, and Knopp; and received payments to support US Food and Drug Administration approval meetings from GlaxoSmithKline; has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Teva, and Chiesi; has received a grant from Chiesi to support a phase 2 clinical trial in Oxford; and was an expert witness in 2014-2105 for a patent dispute involving Astra Zeneca and Teva. V. J. Erpenbeck is a former employee of Novartis. D. A. Sandham is a current employee of Novartis. G. Ogg has received research grants and consultancies or served on advisory boards for UCB, Celgene, AnaptysBio, Sanofi/Genzyme, La Roche Posay, Orbit Discovery, Grunenthal, Evelo, Eli Lilly, and Leo. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 6
P. 2329-2333 - juin 2019 Retour au numéro
Article précédent
- The MALT1 locus and peanut avoidance in the risk for peanut allergy
- Alexandra Winters, Henry T. Bahnson, Ingo Ruczinski, Meher P. Boorgula, Claire Malley, Ali R. Keramati, Sameer Chavan, David Larson, Karen Cerosaletti, Peter H. Sayre, Marshall Plaut, George Du Toit, Gideon Lack, Kathleen C. Barnes, Gerald T. Nepom, Rasika A. Mathias, Immune Tolerance Network LEAP Study Team
- Sample procedure in peripheral blood mononuclear cells RNA sequencing
- Gen Lu, Jian-Hua Ren, Bo Hu, Chun-Hui He, Pei-Qiong Wu, Wen-Hui Jiang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?